<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740543</url>
  </required_header>
  <id_info>
    <org_study_id>10-01191</org_study_id>
    <nct_id>NCT02740543</nct_id>
  </id_info>
  <brief_title>Biomarkers of Irritant-Induced and Allergic Asthma</brief_title>
  <official_title>Biomarkers of Irritant-Induced and Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a heterogeneous disease, and although much is understood about mechanisms of&#xD;
      inflammation in allergic asthma, less is known about mechanisms of irritant-induced asthma&#xD;
      (IA). Understanding the underlying similarities and differences in mechanisms of these two&#xD;
      types of asthma will help focus current treatments and lead to development of new therapies.&#xD;
      There is a longstanding NYU/Bellevue Asthma registry (NYUBAR), with a large population (N =&#xD;
      900) of asthma cases and controls, a program that has been housed at the CTSI (formerly&#xD;
      GCRC). The destruction of the World Trade Center (WTC) resulted in massive dust, gas and fume&#xD;
      exposures to local residents, workers and cleanup workers and individuals involved in rescue&#xD;
      and recovery and adverse respiratory health effects of this disaster are reported more than 7&#xD;
      years after 9/11. Many responders, as well as those exposed as residents or local workers,&#xD;
      have developed IA, asthma that arises after a lag from an environmental exposure . The WTC&#xD;
      Environmental Health Center (WTC EHC) is one of the three New York City (NYC) WTC Centers of&#xD;
      Excellence and the only one that focuses on treatment and monitoring of local workers and&#xD;
      residents. As such, it has a large population of individuals with irritant-induced asthma. It&#xD;
      has been proposed to use participants from the NYUBAR and the WTC EHC to expand the knowledge&#xD;
      of irritant and allergic asthma. Non-invasive studies allow for the assessment of airway&#xD;
      inflammation, a non-specific response to environmental exposure and injury. Recent&#xD;
      technologies also allow for assessment of microRNA (miRNA), small RNAs that regulate gene&#xD;
      expression at the post-transcriptional level and thus serve as a pathway to regulation of&#xD;
      inflammation. The hypothesis will be tested in that airway inflammation in irritant and&#xD;
      allergic asthma may be similar, but result from divergent miRNA regulatory pathways expressed&#xD;
      in sputum cells. These studies will provide preliminary data for future studies that will&#xD;
      help identify biological pathways to categorize these asthma phenotypes and target future&#xD;
      treatment interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have two asthma phenotypes and one control population. Patients will be&#xD;
      recruited from the WTC EHC = 30 with WTC dust cloud exposure, patients will be recruited from&#xD;
      the NYUBAR (n=30) and have asthma as defined by NIH guidelines, and control patients will be&#xD;
      recruited from the NYUBAR (n=30) and will have no respiratory sx, no asthma diagnosis, or no&#xD;
      WTC dust exposure.&#xD;
&#xD;
      The study will entail two to three visits. On visit 1 (V1) all individuals will sign informed&#xD;
      consent to participate in the study under an NYU IRB approved protocol. A questionnaire will&#xD;
      be completed with standardized questions that include information on WTC exposures,&#xD;
      demographics, presence and severity of respiratory symptoms, tobacco history and past medical&#xD;
      history. Individuals will undergo spirometry with inhaled bronchodilator. Individuals will&#xD;
      undergo methacholine challenge test (visit 1a) if they have normal spirometry or no bronchial&#xD;
      hyperresponsiveness. On visit 2, individuals will return to undergo ENO, EBC and spirometry&#xD;
      with pre and post bronchodilator maneuvers and induced sputum. Blood will be obtained for CBC&#xD;
      with differential cell count, and assessment of total IgE and allergen-specific IgE. Blood&#xD;
      will also be stored for future analysis of inflammatory markers. Based on experience, there&#xD;
      have been individuals unable to produce enough sputum and thus yield too small a number of&#xD;
      cells. These individuals are excluded from data analysis. In addition, there will also be&#xD;
      subjects who are able to produce sputum and return for repeat sputum testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">October 23, 2019</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TSLP Gene Expression</measure>
    <time_frame>Baseline and Two (2) weeks</time_frame>
    <description>The primary outcome is the change in TSLP gene expression in epithelial cells after 2 weeks of treatment of inhaled corticosteroid compared to no treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Allergic Asthma (AA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate HFA 220</intervention_name>
    <description>Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.</description>
    <arm_group_label>Allergic Asthma (AA)</arm_group_label>
    <other_name>Corticosteroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For the WTC population with Irritant-Induced Asthma (IA):&#xD;
&#xD;
          -  &gt; 18 years of age*&#xD;
&#xD;
          -  Current nonsmoker*&#xD;
&#xD;
          -  &lt; 5 pack year (p-y) history of tobacco use*&#xD;
&#xD;
          -  Spirometry in the past 6 months or on day of evaluation with a bronchodilator*&#xD;
             response of ≥ 12% and 200 ml improvement in FEV*&#xD;
&#xD;
          -  Positive methacholine challenge test (decrease in FEV1*&#xD;
&#xD;
             ≥ 20% (PC20) after inhalation of &lt; 16 mg/ml of methacholine)&#xD;
&#xD;
          -  Inhaled corticosteroid use in previous 1 month or more will be allowed*&#xD;
&#xD;
          -  Patients will be recruited from the WTC EHC and will have WTC dust cloud exposure&#xD;
&#xD;
          -  New symptoms after 9/11&#xD;
&#xD;
          -  Symptoms of wheeze and shortness of breath (&gt; 2x / week) in the 4 weeks before&#xD;
             inclusion (persistent symptoms).&#xD;
&#xD;
        Inclusion for Allergic Asthma Population (AA):&#xD;
&#xD;
          -  All of the above items with an asterisk (*)&#xD;
&#xD;
          -  Patients will be recruited from the NYUBAR or advertisement and will have asthma as&#xD;
             defined by NIH guidelines, persistent symptoms, absence of WTC dust exposure.&#xD;
&#xD;
          -  Participants who will have completed the Phase I of the study and were able to produce&#xD;
             adequate sputum samples.&#xD;
&#xD;
        Inclusion of Control Population:&#xD;
&#xD;
          -  Patients will be recruited from the NYUBAR and will have no respiratory symptoms, no&#xD;
             asthma diagnosis, no WTC dust exposure, no current tobacco use, ≤ 5 p-y history of&#xD;
             tobacco use, and normal spirometry with no bronchodilator response and negative&#xD;
             methacholine challenge in past 6 months.&#xD;
&#xD;
        Inclusion Criteria for Phase II:&#xD;
&#xD;
          -  Successfully completed Phase I&#xD;
&#xD;
          -  Has asthma according to Phase I diagnostic criteria&#xD;
&#xD;
          -  Signed consent to be re-contacted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current Smoker&#xD;
&#xD;
          -  Pulmonary diseases such as Chronic Pulmonary Disease (COPD) or Interstitial Lung&#xD;
             Disease&#xD;
&#xD;
          -  Cardiac Disease&#xD;
&#xD;
          -  Inability to perform lung function or other maneuvers&#xD;
&#xD;
          -  Upper respiratory tract infection within the last 4 weeks&#xD;
&#xD;
          -  FEV1 &lt;60% predicted normal pre-bronchodilator&#xD;
&#xD;
          -  Oral corticosteroid treatment within the last 4 weeks.&#xD;
&#xD;
          -  No vulnerable subjects will be part of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angeliki Kazeros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <results_first_submitted>August 16, 2021</results_first_submitted>
  <results_first_submitted_qc>September 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>World Trade Center</keyword>
  <keyword>WTC</keyword>
  <keyword>Induced Sputum</keyword>
  <keyword>Exhaled Breath Condensate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02740543/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allergic Asthma (AA)</title>
          <description>Fluticasone propionate HFA 220: Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No fluticasone propionate HFA was given to participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allergic Asthma (AA)</title>
          <description>Fluticasone propionate HFA 220: Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No fluticasone propionate HFA was given to participants.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="7"/>
                    <measurement group_id="B2" value="33" spread="8"/>
                    <measurement group_id="B3" value="30" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in TSLP Gene Expression</title>
        <description>The primary outcome is the change in TSLP gene expression in epithelial cells after 2 weeks of treatment of inhaled corticosteroid compared to no treatment.</description>
        <time_frame>Baseline and Two (2) weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergic Asthma (AA)</title>
            <description>Fluticasone propionate HFA 220: Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No fluticasone propionate HFA was given to participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TSLP Gene Expression</title>
          <description>The primary outcome is the change in TSLP gene expression in epithelial cells after 2 weeks of treatment of inhaled corticosteroid compared to no treatment.</description>
          <units>Fold Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000197" spread="0.000134"/>
                    <measurement group_id="O2" value="0.000035" spread="0.000023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Allergic Asthma (AA)</title>
          <description>Fluticasone propionate HFA 220: Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Fluticasone propionate HFA was not given to participant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angeliki Kazeros, MD</name_or_title>
      <organization>NYU Langone Health - Bellevue Hospital</organization>
      <phone>212-263-6479</phone>
      <email>Angeliki.Kazeros@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

